MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- SANDU PHARMA
SANDU PHARMA Share Price 
(SNPH)
Here is the latest stock price and chart of SANDU PHARMA. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Jan 17, 2019 (Close) | ||
|---|---|---|---|
| Price (Rs)27.00 | Open (Rs) 27.00 | High (Rs) 27.00 | Low (Rs) 27.00 |
| % Change-3.23 | Volume 50 | Value (Rs) 1,350 | 52-Week H/L 41.75 / 19.50 |
| Live NSE Quotes |
|---|
| Not listed |
| BSE Sensex | CNX Nifty |
- Charts
-
PERIOD - Advanced Charts new
- Charts by TradingView
SANDU PHARMA Share Price Today:
SANDU PHARMA last traded price was down 3.2% to Rs 27.0 on the BSE. The total volume of shares traded was 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 0.9%. And the benchmark S&P BSE SENSEX was at 36,374.1 (up 0.2%).
Over the last 30 days, the SANDU PHARMA share price is up 6.7%. And over the last one year, SANDU PHARMA share price is down 24.7%.
|
| |
Today's Market
Sensex Ends Marginally Higher; Healthcare and Oil & Gas Stocks Witness Buying(Closing)
Indian share markets continued to trade near the dotted line during closing hours and ended the day marginally higher. Gains were largely seen in the healthcare sector .
Related Views On News
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
Eris Lifesciences Limited (IPO)
Jun 15, 2017Exposure to high margin specialty products offers promising growth prospects.
More Views on NewsMost Popular
Our First Bluechip Stock Recommendation in Smart Money Secrets(The 5 Minute Wrapup)
Jan 9, 2019For the first time, we have recommended a bluechip stock in Smart Money Secrets.
3 Stocks in Super Investor Sumeet Nagar's Portfolio That You Can Buy Right Now(The 5 Minute Wrapup)
Jan 11, 2019The reasons that make these six stocks in Sumeet Nagar's portfolio so compelling
Follow a Super Investor Like This to Multiply Your Wealth(The 5 Minute Wrapup)
Jan 4, 2019Following a super investor can certainly help build a portfolio and create wealth in the long term.
My First Stock Trading Recommendation For 2019(Profit Hunter)
Jan 10, 2019My first trading recommendation for 2019 is a bluechip auto stock. Find out everything about it right away.
HDFC Bank Still Going Strong(Chart Of The Day)
Jan 4, 2019The stock of HDFC Bank has continued to reward shareholders.
MoreTRACK SANDU PHARMA
- Track your investment in SANDU PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.